US20160017062A1 - Antibodies targeted to fungal cell wall polysaccharides - Google Patents

Antibodies targeted to fungal cell wall polysaccharides Download PDF

Info

Publication number
US20160017062A1
US20160017062A1 US14/771,923 US201414771923A US2016017062A1 US 20160017062 A1 US20160017062 A1 US 20160017062A1 US 201414771923 A US201414771923 A US 201414771923A US 2016017062 A1 US2016017062 A1 US 2016017062A1
Authority
US
United States
Prior art keywords
compound
chitin
vaccine
chitosan
fungal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/771,923
Other languages
English (en)
Inventor
Francis Michon
Frank Comer
Kuishu Ren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Vaccines LLC
Original Assignee
Wellstat Vaccines LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Vaccines LLC filed Critical Wellstat Vaccines LLC
Priority to US14/771,923 priority Critical patent/US20160017062A1/en
Assigned to WELLSTAT VACCINES, LLC reassignment WELLSTAT VACCINES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COMER, FRANK I, REN, Kuishu, MICHON, FRANCIS
Publication of US20160017062A1 publication Critical patent/US20160017062A1/en
Assigned to WELLSTAT VACCINES, LLC reassignment WELLSTAT VACCINES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOHLSTADTER, SAMUEL J., REN, Kuishu, MICHON, FRANCIS, COMER, FRANK
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Definitions

  • Candida species are the fourth leading cause of nosocomial sepsis cases in the US and the rising incidence of invasive fungal disease from all pathogenic fungi represents a significant healthcare burden worldwide. Excess healthcare costs due to increased length of stay and treatment of hospital acquired fungal infections are in the range of US$1 thousand million annually in the US alone. Furthermore, comprehensive antifungal susceptibility testing of clinical isolates has made it evident that, despite advances in safe and effective antifungal drugs, all classes of currently available antifungal agents are subject to the emergence of resistant strains (5).
  • Cryptococcal meningitis an infection with the fungus Cryptococcus also known as cryptococcosis
  • Cryptococcosis is a very serious opportunistic infection among people with advanced HIV/AIDS.
  • Cryptococcosis is not contagious, meaning it cannot spread from person-to-person.
  • Cryptococcal meningitis specifically occurs after Cryptococcus has spread from the lungs to the brain.
  • the fundamental utility of the vaccine is dependent on the universality of target antigens.
  • the ⁇ -(1 ⁇ 2)-mannotriose epitope does not appear in all Candida species and the vaccine antigen employing this epitope relies on protective peptide epitopes to expand its utility (10).
  • protective peptide epitopes to expand its utility (10).
  • This invention is designed to target highly conserved fungal cell wall carbohydrate epitopes in order to provide a pan-fungal vaccine.
  • Chitin has not been examined as an antifungal vaccine target, largely for reasons related to its highly insoluble nature. Methods available in the art for degrading chitin into soluble fragments are not stoichiometrically controlled and it is thus difficult to modulate the degree of depolymerization.
  • This invention provides a compound comprising one or more polysaccharide moieties each independently represented by the formula ⁇ (1 ⁇ 4)-[GlcNH—R] n -2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group.
  • This invention also provides a process for manufacturing a compound represented by the formula ⁇ (1 ⁇ 4)-[GlcNH—R] n -2,5-anhydromannose, wherein n is a positive integer from 3 to 500, comprising:
  • This invention provides a method of immunizing a mammalian subject against a fungal infection or pathogen, comprising administering to the subject an immunogenic amount of the compound or a composition containing it.
  • This invention provides a method of stimulating an immune response in a mammalian subject against a fungal pathogen, comprising administering to the subject an immunogenic amount of the compound or a composition containing it.
  • This invention also provides an antibody specific to the compound described above. And it provides a method of protecting a mammalian subject against a fungal infection or pathogen, comprising administering the antibody to the subject in an amount effective to protect the subject against the fungal infection.
  • FIG. 1 Reaction scheme for the preparation of modified chitin fragments.
  • FIG. 2 Analysis of modified chitin conjugation to tetanus toxoid.
  • Coomassie Blue stained SDS-PAGE gel showing conjugation of modified chitin fragments to tetanus toxoid (TT) protein.
  • FIG. 3 Dose and immunization schedule modified chitin-TT conjugate.
  • FIG. 4 Immunogenicity of modified chitin-TT conjugate vaccine in Balb/C mice.
  • FIG. 5A Specificity of immune response in Balb/C mice immunized with modified chitin-TT vaccine conjugate.
  • FIG. 5B Specificity of immune response in Balb/C mice immunized with modified chitin-TT vaccine conjugate.
  • FIG. 5C Specificity of immune response in Balb/C mice immunized with modified chitin-TT vaccine conjugate.
  • Bar graph showing reactivity of vaccine sera toward chitin/chitosan polysaccharides The graph on the left shows that antibodies reactive toward modified chitin can be depleted by adsorption on particulate chitin or chitosan. In addition, soluble extracts from chitin or chitosan inhibit binding of vaccine sera to modified chitin-HSA. The graph on the right shows that binding of an irrelevant antibody (anti-HA) to its epitope is unaffected by the same treatments.
  • anti-HA irrelevant antibody
  • FIG. 6 Binding of modified chitin-TT conjugate vaccine induced antibodies to whole Candida albicans fungi.
  • FIG. 6B Binding of modified chitin-TT conjugate vaccine induced antibodies to whole Candida albicans fungi.
  • FIG. 7A Morphology of Candida albicans yeast cells grown under various conditions Yeast cells grown at 30 C in YPD medium o/n.
  • FIG. 7B Morphology of Candida albicans yeast cells grown under various conditions Intermediate filaments cells grown at 37 C in YPD medium and serum for 150 min.
  • FIG. 7C Morphology of Candida albicans yeast cells grown under various conditions Filaments grown into mycelia at 37 C in YPD medium and serum for 300 min.
  • FIG. 8A Binding of modified chitin and laminarin vaccine-induced antibodies to whole Candida albicans by flow cytometry.
  • Assays controls for antibody binding to yeast cells.
  • FIG. 8B Binding of modified chitin and laminarin vaccine-induced antibodies to whole Candida albicans by flow cytometry.
  • Tetanus toxoid antibody controls binding to yeast cells.
  • FIG. 8C Binding of modified chitin and laminarin vaccine-induced antibodies to whole Candida albicans by flow cytometry.
  • FIG. 8D Binding of modified chitin and laminarin vaccine-induced antibodies to whole Candida albicans by flow cytometry.
  • FIG. 8E Binding of modified chitin and laminarin vaccine-induced antibodies to whole Candida albicans by flow cytometry.
  • FIG. 9A Modified chitin-TT vaccine mediated protection from a lethal challenge of C. albicans
  • mice (Balb/C) were immunized with a modified chitin-TT vaccine and subsequently challenged with a lethal dose of live C. albicans . Survival was monitored for 36 days after fungal challenge.
  • FIG. 9B Modified chitin-TT vaccine mediated protection from a lethal challenge of C. albicans
  • mice were immunized with a modified chitin-TT and laminarin-TT conjugate vaccines and subsequently challenged with a lethal dose of live C. albicans . Survival was monitored for 28 days after fungal challenge.
  • FIG. 10A Immunoreactivity by ELISA of normal human sera with chitin; modified chitin and laminarin
  • FIG. 10B Immunoreactivity by ELISA of normal human sera (NHS) with chitin; modified chitin and laminarin
  • FIG. 10C Immunoreactivity by ELISA of normal human sera with chitin; modified chitin and laminarin
  • FIG. 10D Immunoreactivity by ELISA of normal human sera with chitin; modified chitin and laminarin
  • FIG. 11 Binding of modified chitin and laminarin vaccine-induced antibodies to whole Cryptococcus neoformans type A (H99) by flow cytometry.
  • This invention provide s compound comprising one or more polysaccharide moieties each independently represented by the formula ⁇ (1 ⁇ 4)-[GlcNH—R] n -2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group. In more specific embodiments of this invention, n is a positive integer from 3 to 100, or from 6 to 50. In an embodiment the acyl group R is an acetyl. In another embodiment at least 30% of the acyl groups in the compound are acetyl.
  • the technical field is prevention, treatment, and detection of fungal infections.
  • vaccines or immunotherapeutics that target carbohydrate components of the fungal cell wall can provide treatment for disseminated or locally invasive fungal infections.
  • the disease indications are numerous, including, but not limited to those caused by human pathogenic forms of Candida, Aspergillus , and Cryptococcus species.
  • the ability to generate an antibody response to the conserved carbohydrate components of these pathogenic fungi could lead to the development of diagnostic reagents for detection of these fungal agents in patient biological samples (eg. plasma, serum, or other bodily fluids, as well as tissue sections, etc.).
  • Th2 type inflammatory responses to chitin have been implicated in allergic asthma and other allergic conditions (2), a chitin based vaccine that results in a shift toward a Th1 type immune response may ameliorate the symptoms of allergen induced inflammation.
  • ⁇ -1,3-glucan Another fundamental cell wall carbohydrate of interest is the surface ⁇ -1,3-glucan.
  • Successful infection by fungal pathogens depends on subversion of host immune mechanisms that detect conserved cell wall components such as beta-glucans.
  • a less common polysaccharide, ⁇ -(1,3)-glucan is a cell wall constituent of most fungal respiratory pathogens and has been correlated with pathogenicity or linked directly to virulence.
  • ⁇ -(1,3)-glucan is present in the outermost layer of the Histoplasma capsulatum yeast cell wall and contributes to pathogenesis by concealing immunostimulatory beta-glucans from detection by host phagocytic cells.
  • targeting the fungal ⁇ -1,3-glucan for example, by conferring ⁇ -1,3-glucanase activity to crop plants or applying an inhibitor of the fungal ⁇ -1,3-glucan synthase might provide a versatile strategy for the prevention of a wide variety of fungal diseases in important crops.
  • the detailed mechanism is still remains to be solved, the fact is that the removal of the surface ⁇ -1,3-glucan rapidly activates the defenses responses of the host plant against the fungal pathogens prior to the fungal invasion, resulting in the inhibition of pathogen infection (26).
  • Yeast cell walls are critical for maintaining cell integrity, particularly in the face of challenges such as growth in mammalian hosts.
  • the pathogenic fungus Cryptococcus neoformans additionally anchors its polysaccharide capsule to the cell surface via ⁇ (1-3) glucan in the wall.
  • Cryptococcal cells disrupted in their alpha glucan synthase gene were sensitive to stresses, including temperature, and showed difficulty dividing. These cells lacked surface capsule, although they continued to shed capsule material into the environment. Electron microscopy showed that the alpha glucan that is usually localized to the outer portion of the cell wall was absent, the outer region of the wall was highly disorganized, and the inner region was hypertrophic.
  • a vaccine comprising chitin/chitosan and one or more glucan antigens, for example glucan antigens containing homopolymers of ⁇ -1,3 linkagers, ⁇ -1,3 linkages or both, will target highly conserved fungal cell wall epitopes and provide a pan-fungal vaccine.
  • This invention provides anti-fungal conjugate vaccines that target conserved carbohydrate cell wall components that are common structural elements across multiple phyla of pathogenic fungi.
  • the composition of these vaccines can include one or more epitopes consisting of oligosaccharides or polysaccharides derived from chitin, alone or in combination with ⁇ -mannan or glucan epitopes.
  • the carbohydrate components may be conjugated to an appropriate immunogenic protein carrier, such as tetanus toxoid, diptheria toxoid, or specific protein virulence factors present on the fungal cell surface.
  • the carrier protein is covalently linked directly to the one or more polysaccharide moieties at the anhydromannose group of each of the polysaccharide moieties.
  • the carrier protein is covalently linked to the one or more polysaccharide moieties via one or more immunogenic scaffold moieties.
  • Any conventional scaffold moiety can be used, examples of which include a polysaccharide, a peptidoglycan, a polypeptide, and a polyglycerol.
  • the scaffold can be linear or dendrimeric.
  • Envisioned multicomponent vaccines can include, but are not limited to, a simple mixture of chitin, ⁇ -mannan and/or glucan epitopes (linear ⁇ -1,3- and/or ⁇ -1,3-glucans) or derivatives conjugated individually to a carrier protein or immunogenic scaffold of choice.
  • the ⁇ -mannan can be a ⁇ -1,2-mannose tetrasaccharide.
  • the oligosaccharides can be reacted with a modified chitin polysaccharide, to produce a multivalent molecule.
  • the ⁇ -1,2 mannose tetrasaccharide can be chemically synthesized (23).
  • the condensation of the oligosaccharide can be accomplished by any of numerous methods available in the art for reaction between the reducing end of the oligosaccharide with the free amino groups of the modified chitin or via a spacer arm equipped with a squarate group (23).
  • the invention envisions a further step of conjugating the scaffolded oligosaccharide/polysaccharide to a suitable carrier protein.
  • This conjugation may be achieved by a number of means available to a practitioner skilled in the art.
  • the scaffold complex can be conjugated directly by reductive amination, or indirectly by employing a suitable cross-linker containing a spacer length suitable to relieve steric hindrance between the carbohydrate construct and the carrier protein.
  • a dendrimeric polysaccharide scaffold can be prepared by first reacting the scaffold component with a multifunctional cross-linking reagent, such as Tris-succinimidyl-aminotriacetate (TSAT). This reaction would yield a multivalent array of available scaffolds, in a dendrimer like pattern, for subsequent condensation of the ⁇ -1,2 mannose oligosaccharides component.
  • TSAT Tris-succinimidyl-aminotriacetate
  • the different carbohydrate components can be chemically cross linked, either directly or indirectly.
  • the carbohydrates can be joined by linking them together on a common scaffold matrix, such as a dendrimeric substrate, or by co-conjugation to a protein carrier.
  • a common scaffold matrix such as a dendrimeric substrate
  • co-conjugation to a protein carrier is another embodiment.
  • directly scaffold the components together by creating chemical cross links between the carbohydrate components and subsequently conjugating the scaffolded polysaccharide matrix to an immunogenic protein or peptide carrier.
  • These chemical cross links can be achieved by any number of means available to a practioner skilled in the art, including, but not limited to reductive amination or the use of heterobifunctional or homobifunctional chemical cross linking reagents.
  • This invention provide a composition comprising the compound as described above, wherein for at least 80% of molecules of the compound in the composition n has a value from 6 to 50. In an alternative embodiment, this invention provides a composition comprising molecules of the compound as described above, wherein the mean value of n is from 10 to 50.
  • nitrous deamination included varying the mole fraction of nitrous acid and starting with chitosan of varying size and degree of acetylation. In all of these cases, the nitrous acid treatment solubilized the chitosan suspensions, but the reaction was difficult to control and once again, the yield of oligosaccharides of the desired size was low.
  • chitin was treated with NaOH to effect a limited de-N-acetylation prior to nitrous deamination. This treatment only produced chitin oligosaccharides of very low molecular weight.
  • acylation e.g., acetylation
  • acetylation is not catalytic in nature
  • whether the reaction could be controlled by adjusting the mole fraction of acetylating reagent present in the reaction was tested.
  • the quantity of acylating (e.g., acetylating) reagent it was found that one could directly control the size of the chitin derived fragments in the subsequent nitrous deamination reaction.
  • the two reactions leading from chitosan to modified chitin fragments could be performed as a one pot reaction, consisting of a solid phase acylation (e.g., acetylation) reaction, followed by acidification and nitrous deamination to yield modified chitin fragments.
  • acylating agent for example acetic anhydride or acetyl chloride, both of which are acetylating agents, or N-propionic anhydride or propionic chloride, which are propionylating agents.
  • a major impediment to employing chitin in a vaccine formulation is its highly insoluble nature. Methods available in the art for degrading chitin into soluble fragments are not stoichiometrically controlled and it is thus difficult to modulate the degree of depolymerization. The aim was to efficiently produce chitin derived fragments of sufficient size to induce vaccine responses against native chitin polymers in the fungal cell wall, while also meeting the potentially competing criteria that the fragments be soluble or sufficiently uniform that they are suitable for formulation as an injectable vaccine. The non-limiting examples below demonstrate how success was achieved in meeting these criteria in a one pot reaction.
  • This invention provides a method of immunizing a mammalian subject against a fungal infection, comprising administering to the subject an immunogenic amount of a compound or composition as described above.
  • the subject can be a human or non-human animal.
  • Tetanus toxoid is a non-limiting example of an immunogenic protein that contains multiple T-helper epitopes which make it suitable for use as a protein carrier for carbohydrate conjugate vaccines.
  • Example 2 and FIG. 2 demonstrate a non-limiting example of a method for conjugation of the aldehyde containing chitin fragments to tetanus toxoid via reductive amination.
  • Example 3 and FIG. 3 provide a typical example of an immunization strategy to induce vaccine responses in test animals.
  • albicans was substantially inhibited with modified chitin fragments, demonstrating that a significant portion of the serum antibodies recognize chitin and, importantly, that the antibodies recognize chitin in the native fungus.
  • Antigen inhibition experiments verified the specificity of the vaccine response toward the immunizing antigen (Example and FIG. 5A ). Furthermore, the induced antibodies showed no detectable cross reactivity with multiple GlcNAc containing glycoconjugates that are present in mammals (Example 5B and FIG. 5B ).
  • modified chitin antibodies as well as beta-glucan antibodies were also examined by flow cytometry.
  • Yeast cells followeding overnight incubation at 300 C
  • mycelial (filament) forms were obtained by culture in YPD medium containing serum ( FIG. 7A-C ).
  • mice that received a single cell wall component vaccine comprising a modified chitin-tetanus toxoid conjugate, showed partial protection against a 100% lethal dose of live C. albicans (Example 7 and FIGS. 9A and 9B ).
  • the same modified chitin-tetanus toxoid conjugate vaccine displayed similar partial protection against live C.
  • the vaccine produced as outlined in the preceding specification can be formulated in a pharmaceutically acceptable carrier, such as phosphate buffered saline, normal saline or other appropriate carrier. Additionally, the vaccine can optimally include one or more adjuvants to augment the immunogenecity and/or efficacy. Adjuvants can be added directly to the vaccine compositions or can be administered separately, either concurrently with or shortly after, administration of the vaccine. Without limitation, suitable adjuvants include a variety of adjuvants known in the art, either alone or in combination.
  • Non-limiting examples are an aluminum salt such as aluminum hydroxide gel or aluminum phosphate or alum, but can also be a salt of calcium, magnesium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatized saccharides, or polyphosphazenes.
  • Adjuvants can also be selected, for example, from a variety of oil in water emulsions, Toll like receptors agonists, (ex Toll like receptor 2 agonist, Toll like receptor 3 agonist, Toll like receptor 4 agonist, Toll like receptor 7 agonist, Toll like receptor 8 agonist and Toll like receptor 9 agonist), saponins or combinations thereof.
  • a vaccine composition yielding a productive antibody response may be used in multiple ways.
  • the vaccine may be used for direct immunization of patients at risk for fungal infection.
  • the compounds and compositions of the present invention may be used to isolate or generate antibodies to the compounds of the invention. Isolated antibodies might be prepared, either polyclonal or monoclonal in nature, using known methods available in the art.
  • the compounds of the invention may be used to screen human antibody phage display libraries, by methods well known to practitioners skilled in the art.
  • the compositions described herein may be used to elicit an antibody response in an appropriate host and the resulting antibodies may be immortalized by hybridoma technology, using known methods well established in the art.
  • the compounds described herein may be used to directly produce human antibodies using human B-cell hybridoma technology. Any antibodies thus produced may be used to confer passive protection, either for prophylactic or therapeutic use.
  • Non-limiting examples for uses of these isolated antibodies might include direct protection against fungal disease via immunotherapy, combination therapy with existing anti-fungal agents, or immunoconjugate preparation, eg. direct conjugation to anti-fungal agents.
  • these antibodies can be used to develop a diagnostic platform for detection of fungal infection in patient samples.
  • antibody and “antibodies” include, but are not limited to, monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, camelised antibodies, chimeric antibodies, single-chain Fvs (scFv), single chain antibodies, single domain antibodies, Fab fragments, F(ab′) fragments, etc., and epitope-binding fragments of any of the above.
  • chitin deacetylases to produce chitosan and there is evidence that a mixture of chitin/chitosan polymers may be necessary for proper cell wall integrity and function (19, 20).
  • NMR data on the modified chitin fragments shows some residual free amino groups, raising the possibility that the vaccine can target both pure chitin as well as chitosan containing regions in the chitinous cell wall.
  • ⁇ -mannan and ⁇ -glucan polymers comprise the fundamental carbohydrate constituents of the fungal cell wall.
  • Vaccine induced antibodies that target specific ⁇ -mannan or ⁇ -glucan carbohydrates have been shown to confer protection against fungal disease, displaying both vaccine based efficacy and passive protection (9-11).
  • chitin has not been examined as an anti-fungal vaccine target. In vivo, these three carbohydrate components are covalently cross linked to form the cell wall lattice (21, 22).
  • Vaccine formulations consisting of modified chitin alone, or a combination of two or more of the conserved carbohydrate epitopes of the fungal cell wall, are contemplated to produce a broadly protective vaccine response.
  • Such a combination vaccine could be designed either as a co-administered mixture or as a cross linked scaffold that more closely mimics the surface topography of the fungal cell wall. It is anticipated that these vaccines will be highly effective at inducing a pan fungal immune response.
  • mice 40 female Balb/C mice were received and housed under standard day/night cycles with food and water, ad libitum. The animals were allowed to acclimate to the facility for a minimum of one week, then randomly divided into four groups and immunized as follows:
  • mice were bled and serum was prepared 4 days prior to the initial injection (Study Day ⁇ 4), in order to determine antibody titers in pre-immune serum. Mice were immunized on Study Day 0 according to the experimental groups outlined above.
  • the LMW Chitin-TT antigen was suspended in PBS at concentrations of 0.25, 0.5 and 1.0 mg/mL, mixed with Freund's Complete adjuvant at a 1:1 ratio, and vortexed for 20 minutes to create an emulsion. 200 ⁇ L of emulsion containing PBS/Freund's control or the test antigens (final conc.
  • C. albicans from frozen stock were streaked on an SDA plate and incubated at 30 C.
  • a single colony from the SDA plate was picked using inoculating loop and inoculated into a 250-ml flask containing 50 ml of YPD and incubated at 30 C with shaking at 150 rpm for at least 18 h.
  • the cells were incubated at 37 C for 150 minutes and 300 minutes in YPD containing serum following O/N incubation to induce and favor differentiation into mycelia stage of candida .
  • the O/N culture was transferred into a 50 ml tube and centrifuged at 1000 g for 20 mins and the pellet was washed with 2 ml PBS solution at least 3 times. The pellet was resuspended in 2 ml PBS and the concentration was adjusted to 0.1 OD600 (4 ⁇ 106/ml).
  • the O/N culture was transferred into a 50 ml tube and centrifuged at 1000 g for 20 mins and the pellet was washed with 2 ml PBS solution at least 3 times. The pellet was resuspended in 2 ml PBS and the concentration was adjusted to 1.0 OD600 reading (4 ⁇ 10 7/ml).
  • mice sera from various vaccine groups was diluted in 1:10, 1:50 and 1:100 in PBS and used at 15 ul volume/tube.
  • the control antibodies were diluted as: Mouse mAb to candida, 1:5, 1:10 and 1:20 dilutions; For Rabbit pAb to candida, 1:50, 1:100 and 1:200 dilutions and used at 20 ul volume/tube.
  • FITC-labeled secondary antibodies were diluted 1:25 in PBS and used at 15 ul/tube. Propidium Iodide was used at 1:2 in PBS (5 ul/tube).
  • mice/group randomly divided into groups
  • Groups 1 and 2 comprise animals from PBS (mock) immunized animals
  • HSA human serum albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
US14/771,923 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides Abandoned US20160017062A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/771,923 US20160017062A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361777631P 2013-03-12 2013-03-12
PCT/US2014/021128 WO2014158963A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides
US14/771,923 US20160017062A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/021128 A-371-Of-International WO2014158963A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/583,396 Continuation US10259888B2 (en) 2013-03-12 2017-05-01 Antibodies targeted to fungal cell wall polysaccharides

Publications (1)

Publication Number Publication Date
US20160017062A1 true US20160017062A1 (en) 2016-01-21

Family

ID=51625093

Family Applications (6)

Application Number Title Priority Date Filing Date
US14/771,923 Abandoned US20160017062A1 (en) 2013-03-12 2014-03-06 Antibodies targeted to fungal cell wall polysaccharides
US15/583,396 Expired - Fee Related US10259888B2 (en) 2013-03-12 2017-05-01 Antibodies targeted to fungal cell wall polysaccharides
US16/267,430 Active US10519253B2 (en) 2013-03-12 2019-02-05 Antibodies targeted to fungal cell wall polysaccharides
US16/666,503 Active US10752704B2 (en) 2013-03-12 2019-10-29 Antibodies targeted to fungal cell wall polysaccharides
US16/928,545 Active US10988552B2 (en) 2013-03-12 2020-07-14 Antibodies targeted to fungal cell wall polysaccharides
US17/210,124 Abandoned US20210301037A1 (en) 2013-03-12 2021-03-23 Antibodies Targeted to Fungal Cell Wall Polysaccharides

Family Applications After (5)

Application Number Title Priority Date Filing Date
US15/583,396 Expired - Fee Related US10259888B2 (en) 2013-03-12 2017-05-01 Antibodies targeted to fungal cell wall polysaccharides
US16/267,430 Active US10519253B2 (en) 2013-03-12 2019-02-05 Antibodies targeted to fungal cell wall polysaccharides
US16/666,503 Active US10752704B2 (en) 2013-03-12 2019-10-29 Antibodies targeted to fungal cell wall polysaccharides
US16/928,545 Active US10988552B2 (en) 2013-03-12 2020-07-14 Antibodies targeted to fungal cell wall polysaccharides
US17/210,124 Abandoned US20210301037A1 (en) 2013-03-12 2021-03-23 Antibodies Targeted to Fungal Cell Wall Polysaccharides

Country Status (10)

Country Link
US (6) US20160017062A1 (en27)
EP (1) EP2968427B1 (en27)
JP (2) JP6434958B2 (en27)
CN (1) CN105188725B (en27)
AU (1) AU2014241492A1 (en27)
DK (1) DK2968427T3 (en27)
ES (1) ES2936811T3 (en27)
FI (1) FI2968427T3 (en27)
PL (1) PL2968427T3 (en27)
WO (1) WO2014158963A1 (en27)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259888B2 (en) * 2013-03-12 2019-04-16 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111707815A (zh) * 2019-12-31 2020-09-25 安徽中医药大学 一种通过白色念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法
CN113274489B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种预防真菌感染的几丁质寡糖疫苗及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62138496A (ja) 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
JP2871822B2 (ja) * 1989-08-29 1999-03-17 玉造株式会社 末端に２，５―アンヒドロマンニトール基または２，５―アンヒドロマンノース基を有するキチン・キトサンオリゴマーおよびその製造方法
JP2786389B2 (ja) * 1993-05-18 1998-08-13 玉造株式会社 腫瘍免疫治療剤
US5705634A (en) 1995-03-02 1998-01-06 Perimmune Holdings, Inc. High yield preparation of dimeric to decameric chitin oligomers
US6284884B1 (en) * 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7098194B2 (en) * 2001-11-15 2006-08-29 Biosyntech Canada, Inc. Composition and method to homogeneously modify or cross-link chitosan under neutral conditions
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
EP1863536A4 (en) * 2005-03-14 2011-07-20 Univ Alberta VACCINE BASED ON SYNTHETIC OLIGOSACCHARIDES AGAINST CANDIDA ALBICANS
WO2006134614A1 (en) 2005-06-14 2006-12-21 Genis Ehf. Compositions of partially deacetylated chitin derivatives
KR100793756B1 (ko) * 2006-08-07 2008-01-10 엘지전자 주식회사 녹화 목록 표시 방법 및 그 장치
US20080311595A1 (en) 2007-06-18 2008-12-18 Inger Mattsby-Baltzer Rapid fungal detection assay and product
GB2460966B (en) * 2008-03-13 2010-05-19 Academia Sinica Fibrillar fibronectin and uses thereof
EP2123261A1 (en) 2008-05-20 2009-11-25 Stallergenes S.A. Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
KR101785373B1 (ko) 2008-07-21 2017-10-16 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
US20110274713A1 (en) * 2008-08-05 2011-11-10 The University Of Queensland Antigen-presenting scaffolds
RU2498818C2 (ru) 2008-09-05 2013-11-20 Сева Санте Анималь Са Композиция, содержащая хитозан, для глазного введения вакцины (вакцин) птицам
JP5459874B2 (ja) * 2008-10-23 2014-04-02 ザ ルブリゾル コーポレイション 金属カルボン酸塩を含む潤滑組成物
JP5617127B2 (ja) * 2009-05-08 2014-11-05 大石　哲也 新規グアナミン化合物、その誘導体及びそれらの製造方法
ES2707778T3 (es) * 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
JP2012241084A (ja) * 2011-05-18 2012-12-10 Nippon Terupen Kagaku Kk バインダー樹脂用溶剤
WO2014158963A1 (en) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10259888B2 (en) * 2013-03-12 2019-04-16 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
US10519253B2 (en) 2013-03-12 2019-12-31 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
US10752704B2 (en) 2013-03-12 2020-08-25 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
US10988552B2 (en) 2013-03-12 2021-04-27 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides

Also Published As

Publication number Publication date
EP2968427A4 (en) 2016-08-31
EP2968427A1 (en) 2016-01-20
HK1220360A1 (en) 2017-05-05
US20190169315A1 (en) 2019-06-06
US10752704B2 (en) 2020-08-25
JP2018172696A (ja) 2018-11-08
CN105188725A (zh) 2015-12-23
JP2016513747A (ja) 2016-05-16
US10259888B2 (en) 2019-04-16
DK2968427T3 (da) 2023-01-30
US10519253B2 (en) 2019-12-31
US20200062866A1 (en) 2020-02-27
FI2968427T3 (fi) 2023-03-01
US10988552B2 (en) 2021-04-27
AU2014241492A1 (en) 2015-09-17
CN105188725B (zh) 2020-08-21
PL2968427T3 (pl) 2023-02-27
US20210301037A1 (en) 2021-09-30
WO2014158963A1 (en) 2014-10-02
US20200339707A1 (en) 2020-10-29
EP2968427B1 (en) 2022-10-26
JP6434958B2 (ja) 2018-12-05
ES2936811T3 (es) 2023-03-22
US20180251573A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
US10988552B2 (en) Antibodies targeted to fungal cell wall polysaccharides
BE1022792B1 (fr) Molecule support
Liao et al. Synthesis and immunological studies of linear oligosaccharides of β-glucan as antigens for antifungal vaccine development
CN104080479B (zh) 包括spr0096和spr2021抗原的运载体分子
JP2016526574A (ja) 部位特異的化学酵素的タンパク質修飾
Khatun et al. Immunogenicity assessment of cell wall carbohydrates of Group A Streptococcus via self-adjuvanted glyco-lipopeptides
Patel et al. Immunological outcomes of antibody binding to glycans shared between microorganisms and mammals
HK1220360B (en) Conjugate for inducing antibodies targeting fungal cell wall polysaccharides
US20250186596A1 (en) A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
US20250186595A1 (en) A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
US20220117997A1 (en) Polysaccharide compositions for use in treating filariasis
TW202409077A (zh) 由至少一β-葡聚糖或甘露多醣組成或包含其之結合物
AT525943A2 (de) Konjugat bestehend aus oder umfassend zumindest ein ß-Glucan oder ein Mannan

Legal Events

Date Code Title Description
AS Assignment

Owner name: WELLSTAT VACCINES, LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MICHON, FRANCIS;COMER, FRANK I;REN, KUISHU;SIGNING DATES FROM 20140814 TO 20140818;REEL/FRAME:033589/0157

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: WELLSTAT VACCINES, LLC, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MICHON, FRANCIS;WOHLSTADTER, SAMUEL J.;COMER, FRANK;AND OTHERS;SIGNING DATES FROM 20181211 TO 20181219;REEL/FRAME:047814/0662